Cloudbreak Pharma (HKSE:02592) Research & Development: HK$521.38 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02592 Cloudbreak Pharma Inc HKSE:02592
11 GF Score
Price HK$1.20
! 2 Warning Signs
View Full Analysis

What is Cloudbreak Pharma Research & Development?

Cloudbreak Pharma HKSE:02592 -1.64% 11 Research & Development is HK$521.38 Mil as of Dec. 2025. GuruFocus rates HKSE:02592 with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Cloudbreak Pharma's Research & Development for the six months ended in Dec. 2025 was HK$335.12 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$521.38 Mil.

Cloudbreak Pharma  (HKSE:02592) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Cloudbreak Pharma Research & Development Related Terms

Cloudbreak Pharma Research & Development Historical Data

* Premium members only.

The historical data trend for Cloudbreak Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cloudbreak Pharma Research & Development Chart

Cloudbreak Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Research & Development
119.04 214.71 294.97 519.77

Cloudbreak Pharma Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial 0.00 175.62 120.17 186.26 335.12
HKSE:02592
11GF Score
Cloudbreak Pharma Inc HKSE:02592
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cloudbreak Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$521.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$521.38 Mil mean?
Cloudbreak Pharma (HKSE:02592) has a Research & Development of HK$521.38 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Cloudbreak Pharma and its competitors.
Is Cloudbreak Pharma's Research & Development too high?
Cloudbreak Pharma's current Research & Development is HK$521.38 Mil. Overall, Cloudbreak Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Cloudbreak Pharma's Research & Development compare to VRTX and REGN?
Cloudbreak Pharma's Research & Development of HK$521.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Cloudbreak Pharma and its competitors. Cloudbreak Pharma's current Research & Development is HK$521.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cloudbreak Pharma stock overvalued right now?
Cloudbreak Pharma (HKSE:02592) has a current Research & Development of HK$521.38 Mil. The current Research & Development is HK$521.38 Mil. Cloudbreak Pharma's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Cloudbreak Pharma (HKSE:02592), the current Research & Development is HK$521.38 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cloudbreak Pharma Business Description

Address 8921 Research Drive, Irvine, CA, USA, 92618
Cloudbreak Pharma Inc is engaged in research and development of ophthalmology biotechnology. The company is a clinical-stage ophthalmology biotechnology company focused on developing treatments for ophthalmic diseases through the proprietary drug discovery and development capabilities, with operations based in the United States and China. The pipeline currently consists of nine drug candidates targeted for treatment of anterior and posterior ophthalmic diseases, including five clinical-stage and four pre-clinical stage candidates. The drugs in the pipeline include CBT-001, CBT-004, CBT-009, and CBT-199.
11GF Score

Get the complete analysis for HKSE:02592

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.20
Price